Nov 30, 2016 13:00 pm UTC| Business
DALLAS, Nov. 30, 2016 -- McElhenny Sheffield Capital Management(MSCM) is pleased to announce the execution of a Succession Plan Agreement with Inspire Capital Management as part of Inspire Capital’s continuing...
Nov 30, 2016 13:00 pm UTC| Business
LAWRENCEVILLE, N.J., Nov. 30, 2016 -- Celsion Corporation(NASDAQ:CLSN) today announced that following a review of data from its multinational, randomized pivotal Phase III clinical study of ThermoDox® in combination...
Nov 30, 2016 13:00 pm UTC| Business
ROMAINVILLE, France, Nov. 30, 2016 -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces the successful completion of its...
Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics
Nov 30, 2016 13:00 pm UTC| Business
SAN DIEGO and LONDON, Nov. 30, 2016 -- Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. Viracta plans to advance VRx-3996...
Nov 30, 2016 13:00 pm UTC| Business
PARIS and TOULOUSE, France, Nov. 30, 2016 -- Genticel (Euronext Paris Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies, today announced that a...
Nov 30, 2016 12:32 pm UTC| Business
VANCOUVER, British Columbia, Nov. 30, 2016 -- Pure Energy Minerals Limited (TSX VENTURE:PE) (FRANKFURT:A111EG) (OTCQB:PEMIF) (the “Company” or “Pure Energy”) is pleased to announce that it has commenced drilling its...
Nov 30, 2016 12:30 pm UTC| Business
CARMIEL, Israel, Nov. 30, 2016 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been enrolled in its phase II clinical trial of OPRX-106 for the treatment of...